Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

结直肠癌（CRC）是全球范围内发病率和死亡率较高的恶性肿瘤之一。HER2 基因扩增在 CRC 中的发生率仅为 3%～5%[1]，但与其预后密切相关，并已成为新的治疗靶点。随着新型 HER2 靶向治疗的出现，针对 HER2 ...

If your healthcare provider has confirmed that your HER2+ and ER+ breast cancer has spread or cannot be surgically removed, it’s crucial to work closely with your healthcare team to develop a ...

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.

which enrolled patients with HER2-low unresectable, metastatic breast cancer who received multiple lines of prior treatment, and was headlined at last year's ASCO congress. In the 557-patient ...

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for patients with HR-positive, HER2-negative breast cancer. The FDA has approved ...

The EMBER-3 study introduced imlunestrant, an oral selective estrogen receptor degrader (SERD), as a potential treatment for hormone receptor–positive, HER2-negative metastatic breast cancer ...

The persistence of NK-92/5.28.z cells at tumor sites demonstrates efficient antitumor response, which could help overcome current obstacles in the treatment of solid tumors. Discussion: These findings ...

It is administered by oral route. The drug candidate was also under development for the treatment of estrogen/progesterone receptor-positive or Her2/Neu-positive breast cancer, pancreatic cancer, ...

Breast cancer (BC) is the leading cause of cancer-related mortality among women. The backbone of first-line treatment in HR+/HER2+ BC is dual anti-HER2 blockade combined with taxane chemotherapy.